Dario Riccardo Valenzano, PhD., will present the latest research on the topic African turquoise killifish shed light on evolution and modulation of vertebrate lifespan at the worlds' largest annual. Dr Dario Riccardo Valenzano is the Group Leader at the Max Planck Institute for Biology of Aging and Leibniz Institute on Aging, Fritz Lipmann Institute, Jena, Germany.
Dario Riccardo Valenzano studied neuroscience at the Scuola Normale Superiore in Italy and did a postdoc at Stanford University in the USA. He currently leads a lab at the Max Planck Institute for Biology of Aging and at the Leibniz Institute on Aging, both in Germany. His research team studies the genomic basis of short/long lifespan across species and investigates the role of commensal gut microbes during aging. His main model system is the naturally short-lived turquoise killifish (Nothobranchius furzeri), which he studies in his lab in Cologne and in its natural habitat in the African savannah.
The conference proceedings of the ARDD are commonly published in peer-reviewed journals with the talks openly available at. Please review the conference proceedings for 2019 and 2020.
"Aging is emerging as a druggable condition with multiple pharmaceuticals able to alter the pace of aging in model organisms. The ARDD brings together all levels of the field to discuss the most pressing obstacles in our attempt to find efficacious interventions and molecules to target aging. The 2021 conference is the best yet with top level speakers from around the globe. I'm extremely excited to be able to meet them in person at the University of Copenhagen in late summer.", said Morten Scheibye-Knudsen, MD, Ph.D., University of Copenhagen.
"Aging research is growing faster than ever on both academia and industry fronts. The ARDD meeting unites experts from different fields and backgrounds, sharing with us their latest groundbreaking research and developments. Our last ARDD meeting took place online and was a great success. This year's event will be a hybrid meeting with virtual and in-person attendees. I am particularly excited that being part of the ARDD 2021 meeting will provide an amazing opportunity for young scientists presenting their own work as well as meeting the experts in the field." said Daniela Bakula, Ph.D., University of Copenhagen
"Aging research is gaining traction in the biopharmaceutical industry. To my knowledge, 6 out of the top 30 pharmaceutical companies in the world prioritized aging research for early-stage discovery or therapeutic pipeline development and several companies employ artificial intelligence for this purpose. We organize the annual ARDD conference for eight years in a row and the level of interest in aging biomarkers and noticed exponential growth in registrations over the past two years", said Alex Zhavoronkov, Ph.D., co-founder and CEO of Insilico Medicine, and the founder of Deep Longevity.
Building on the success of the ARDD conferences, the organizers developed the "Longevity Medicine" course series with some of the courses offered free of charge atcovered in the recent Lanced Healthy Longevity paper titled Longevity medicine: upskilling the physicians of tomorrow.